Irina Dijmărescu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irina Dijmărescu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Păcurar
Department of Pediatrics, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
14 shared publications - Alexandru Dinulescu
Faculty of Medicine, Department of Pediatrics, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
11 shared publications - Mihai Andronie
Spiru Haret University
10 shared publications - George Lăzăroiu
Curtin University
8 shared publications - Alexandra Coroleuca
Department of Pediatrics, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Dionisie Lupu Street, No. 37, 020021 Bucharest, Romania
5 shared publications - Cristian Uță
Spiru Haret University
5 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 1997
Phenotypic Variability and Diagnostic Characteristics of Pediatric Osteogenesis Imperfecta: A 10-Year Multicenter Cohort Study from Three Tertiary Pediatric Hospitals in Bucharest, Romania
Background/Objectives: Osteogenesis imperfecta (OI) is a rare hereditary connective tissue disorder characterized by bone fragility, recurrent fractures, and variable extra-skeletal manifestations. There are scarce epidemiological and clinical data from Eastern Europe, including Romania. This study aimed to characterize the phenotypic spectrum and diagnostic features of pediatric OI in a Romanian multicenter cohort. Methods: A retrospective, multicenter observational study was conducted over a 10-year period (January 2014–December 2024) in three tertiary pediatric referral centers in Bucharest, Romania. Children with a diagnosis of OI based on clinical, radiological, and, where available, molecular criteria were included. Clinical, phenotypic, genetic, and therapeutic data were extracted from medical records. Statistical analyses included the Mann–Whitney U test, Kruskal–Wallis test with Bonferroni correction, Fisher’s exact test, Kaplan–Meier survival analysis, and Spearman correlation. Results: Forty-seven patients were included (53.2% female; median age at diagnosis 36 months, IQR 5–87). OI type I was the most frequent subtype (42.6%), followed by type III (29.8%) and type IV (21.3%). Molecular genetic testing was performed in 40.4% of patients; among genetically tested patients, COL1A1 variants represented the most common finding (52.6%). The median number of documented fractures was 5 (IQR 3–9), with a significantly higher annual fracture rate in type III compared to type I (0.99 vs. 0.34 fractures/year, p = 0.019). Short stature was the most frequent skeletal manifestation (66%), with significantly more severe growth impairment in type III compared to type I (−4.38 ± 1.67 vs. −1.56 ± 1.03 SD, p < 0.001). Blue sclerae was present in 87.2% of patients and dentinogenesis imperfecta in 68.1%. Cryptorchidism was identified in 50% of male patients. Developmental motor milestones were significantly delayed in type III OI patients, with 10.6% failing to achieve independent walking by last follow-up. A strong positive correlation was observed between age at first fracture and age at diagnosis (Spearman R = 0.764, p < 0.001), with type I patients diagnosed significantly later than type III (median 71.5 vs. 6.5 months, p = 0.006). Conclusions: This study provides the most comprehensive phenotypic characterization of pediatric OI reported from Romania to date. Our findings confirm established genotype–phenotype correlations and underscore the diagnostic challenge of milder OI forms. The high prevalence of cryptorchidism in male patients represents a clinically relevant finding needing prospective validation. The data highlight the need for expanded molecular diagnostic capacity, increased disease awareness among frontline clinicians, and the development of a national OI registry to support longitudinal research and integration with European rare bone disease networks.
- 26 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 1997
Open AccessPhenotypic Variability and Diagnostic Characteristics of Pediatric Osteogenesis Imperfecta: A 10-Year Multicenter Cohort Study from Three Tertiary Pediatric Hospitals in Bucharest, Romania
Background/Objectives: Osteogenesis imperfecta (OI) is a rare hereditary connective tissue disorder characterized by bone fragility, recurrent fractures, and variable extra-skeletal manifestations. There are scarce epidemiological and clinical data from Eastern Europe, including Romania. This study aimed to characterize the phenotypic spectrum and diagnostic features of pediatric OI in a Romanian multicenter cohort. Methods: A retrospective, multicenter observational study was conducted over a 10-year period (January 2014–December 2024) in three tertiary pediatric referral centers in Bucharest, Romania. Children with a diagnosis of OI based on clinical, radiological, and, where available, molecular criteria were included. Clinical, phenotypic, genetic, and therapeutic data were extracted from medical records. Statistical analyses included the Mann–Whitney U test, Kruskal–Wallis test with Bonferroni correction, Fisher’s exact test, Kaplan–Meier survival analysis, and Spearman correlation. Results: Forty-seven patients were included (53.2% female; median age at diagnosis 36 months, IQR 5–87). OI type I was the most frequent subtype (42.6%), followed by type III (29.8%) and type IV (21.3%). Molecular genetic testing was performed in 40.4% of patients; among genetically tested patients, COL1A1 variants represented the most common finding (52.6%). The median number of documented fractures was 5 (IQR 3–9), with a significantly higher annual fracture rate in type III compared to type I (0.99 vs. 0.34 fractures/year, p = 0.019). Short stature was the most frequent skeletal manifestation (66%), with significantly more severe growth impairment in type III compared to type I (−4.38 ± 1.67 vs. −1.56 ± 1.03 SD, p < 0.001). Blue sclerae was present in 87.2% of patients and dentinogenesis imperfecta in 68.1%. Cryptorchidism was identified in 50% of male patients. Developmental motor milestones were significantly delayed in type III OI patients, with 10.6% failing to achieve independent walking by last follow-up. A strong positive correlation was observed between age at first fracture and age at diagnosis (Spearman R = 0.764, p < 0.001), with type I patients diagnosed significantly later than type III (median 71.5 vs. 6.5 months, p = 0.006). Conclusions: This study provides the most comprehensive phenotypic characterization of pediatric OI reported from Romania to date. Our findings confirm established genotype–phenotype correlations and underscore the diagnostic challenge of milder OI forms. The high prevalence of cryptorchidism in male patients represents a clinically relevant finding needing prospective validation. The data highlight the need for expanded molecular diagnostic capacity, increased disease awareness among frontline clinicians, and the development of a national OI registry to support longitudinal research and integration with European rare bone disease networks.
- Open Access
How Were Functional Somatic Symptoms in Children Influenced by the COVID-19 Pandemic? A Retrospective Study of Children Admitted to a Tertiary Pediatric Emergency Hospital in Bucharest, Romania
Background: Functional somatic symptoms (FSSs) represent a significant clinical challenge in pediatric populations, with prevalence estimates ranging from 10 to 30%. The COVID-19 pandemic introduced unprecedented psychosocial stressors that may have influenced the presentation and precipitating factors of these conditions. This article aimed to characterize the clinical presentations, precipitating factors, and temporal patterns of functional somatic disorders in children admitted to a tertiary pediatric hospital in Bucharest, Romania, across pre-pandemic (2017–2019), pandemic (2020–2022), and post-pandemic (2023–2025) periods. Methods: This retrospective study included 1043 patients aged 3–17 years admitted with somatic symptoms without identifiable organic pathology. Data were extracted using ICD-10 diagnostic codes and confirmed through individual chart review. Variables analyzed included demographics, symptoms, precipitating factors, symptom duration, and family psychiatric history. Results: Female patients predominated (67.0%), with a median age of 14 years. Cardiovascular symptoms were most frequent (43.9%), followed by neurological (30.4%), digestive (19.0%), and respiratory (6.3%) manifestations. Family-related factors (38.6%) and school-related stress (32.7%) were the primary precipitating factors. Significant pandemic-related differences emerged: medical-related precipitating factors increased during the pandemic (18.5% vs. 10.7% pre-pandemic, p < 0.001), respiratory symptoms were more frequent (9.8% vs. 5.9% pre-pandemic), and symptom duration before admission was significantly longer (median 1 vs. 1 pre-pandemic and 0 months post-pandemic; p < 0.001). Conclusions: The COVID-19 pandemic substantially influenced pediatric somatic presentations, with increased health anxiety, respiratory symptoms, and delayed healthcare-seeking behavior. Post-pandemic patterns suggest the persistent influence of traditional stressors alongside pandemic-related effects.
Open AccessHow Were Functional Somatic Symptoms in Children Influenced by the COVID-19 Pandemic? A Retrospective Study of Children Admitted to a Tertiary Pediatric Emergency Hospital in Bucharest, Romania
Background: Functional somatic symptoms (FSSs) represent a significant clinical challenge in pediatric populations, with prevalence estimates ranging from 10 to 30%. The COVID-19 pandemic introduced unprecedented psychosocial stressors that may have influenced the presentation and precipitating factors of these conditions. This article aimed to characterize the clinical presentations, precipitating factors, and temporal patterns of functional somatic disorders in children admitted to a tertiary pediatric hospital in Bucharest, Romania, across pre-pandemic (2017–2019), pandemic (2020–2022), and post-pandemic (2023–2025) periods. Methods: This retrospective study included 1043 patients aged 3–17 years admitted with somatic symptoms without identifiable organic pathology. Data were extracted using ICD-10 diagnostic codes and confirmed through individual chart review. Variables analyzed included demographics, symptoms, precipitating factors, symptom duration, and family psychiatric history. Results: Female patients predominated (67.0%), with a median age of 14 years. Cardiovascular symptoms were most frequent (43.9%), followed by neurological (30.4%), digestive (19.0%), and respiratory (6.3%) manifestations. Family-related factors (38.6%) and school-related stress (32.7%) were the primary precipitating factors. Significant pandemic-related differences emerged: medical-related precipitating factors increased during the pandemic (18.5% vs. 10.7% pre-pandemic, p < 0.001), respiratory symptoms were more frequent (9.8% vs. 5.9% pre-pandemic), and symptom duration before admission was significantly longer (median 1 vs. 1 pre-pandemic and 0 months post-pandemic; p < 0.001). Conclusions: The COVID-19 pandemic substantially influenced pediatric somatic presentations, with increased health anxiety, respiratory symptoms, and delayed healthcare-seeking behavior. Post-pandemic patterns suggest the persistent influence of traditional stressors alongside pandemic-related effects.
- Open Access
- 20 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 927
A Retrospective Description of Pediatric Hepatitis C in a Romanian Cohort: Liver Fibrosis at Diagnosis
Background: Pediatric hepatitis C virus (HCV) infection is often asymptomatic but may lead to significant liver disease later in life. In Romania, data on pediatric HCV remains scarce. This study aimed to describe the clinical and epidemiological characteristics of children with chronic HCV infection in a Romanian cohort. Methods: We conducted a retrospective study that included 83 pediatric patients evaluated for chronic hepatitis C between 1995 and 2024 at a tertiary pediatric hospital from Bucharest, Romania. Demographic data, routes of transmission, biochemical parameters, viral load, and liver fibrosis assessed by FibroScan® or liver biopsy were analyzed. Results: The median age at diagnosis was 73 months (IQR 36–156), with a slight female predominance (54.2%). Vertical transmission was the most common (48.2%). Most children had normal or mildly elevated transaminases at diagnosis. Although pediatric HCV hepatic involvement is generally considered mild, in our cohort only 40.6% of children had absent or mild fibrosis at diagnosis, while in 33.7% of cases moderate fibrosis was identified, and 8.4% had severe fibrosis or cirrhosis. No significant correlations were found between viral load, transaminase levels, and fibrosis severity. Conclusions: Pediatric HCV infection in Romania is frequently diagnosed late, mainly due to the lack of systematic perinatal screening. Although liver disease is generally mild, the cases of advanced fibrosis highlight the need for early diagnosis and improved screening strategies.
- 20 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 927
Open AccessA Retrospective Description of Pediatric Hepatitis C in a Romanian Cohort: Liver Fibrosis at Diagnosis
Background: Pediatric hepatitis C virus (HCV) infection is often asymptomatic but may lead to significant liver disease later in life. In Romania, data on pediatric HCV remains scarce. This study aimed to describe the clinical and epidemiological characteristics of children with chronic HCV infection in a Romanian cohort. Methods: We conducted a retrospective study that included 83 pediatric patients evaluated for chronic hepatitis C between 1995 and 2024 at a tertiary pediatric hospital from Bucharest, Romania. Demographic data, routes of transmission, biochemical parameters, viral load, and liver fibrosis assessed by FibroScan® or liver biopsy were analyzed. Results: The median age at diagnosis was 73 months (IQR 36–156), with a slight female predominance (54.2%). Vertical transmission was the most common (48.2%). Most children had normal or mildly elevated transaminases at diagnosis. Although pediatric HCV hepatic involvement is generally considered mild, in our cohort only 40.6% of children had absent or mild fibrosis at diagnosis, while in 33.7% of cases moderate fibrosis was identified, and 8.4% had severe fibrosis or cirrhosis. No significant correlations were found between viral load, transaminase levels, and fibrosis severity. Conclusions: Pediatric HCV infection in Romania is frequently diagnosed late, mainly due to the lack of systematic perinatal screening. Although liver disease is generally mild, the cases of advanced fibrosis highlight the need for early diagnosis and improved screening strategies.
- Open Access
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1779
Genotype-Phenotype Correlations in Pediatric Hereditary Pancreatitis: Evidence from a Romanian Retrospective Cohort
Objectives: This study aimed to evaluate the genetic and clinical characteristics of hereditary pancreatitis (HP) in a cohort of Romanian pediatric patients, with a focus on the correlation between specific gene mutations and disease severity, recurrence patterns, and associated complications. Methods: A retrospective analysis was conducted on pediatric patients diagnosed with HP. Genetic testing was performed to identify mutations in key genes. Clinical data were collected regarding age of onset, recurrence, severity, surgical interventions, and progression to chronic pancreatitis. Exploratory computational analyses were performed to illustrate potential patterns between genetic variants and clinical characteristics. Results: PRSS1 variants were associated with earlier onset and more severe disease. A substantial proportion of patients developed chronic pancreatitis during the study period. Surgical complications were observed in over half of the cohort. The findings are consistent with the role of genetic mutations in influencing the clinical trajectory of HP. Genotype–phenotype correlations may inform hypotheses regarding early risk stratification and tailored management strategies. Conclusions: Genetic testing is essential for the accurate diagnosis and personalized treatment of HP. Integrating genetic diagnostics into clinical practice may improve outcomes and guide early intervention in high-risk pediatric patients.
- 26 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1779
Open AccessGenotype-Phenotype Correlations in Pediatric Hereditary Pancreatitis: Evidence from a Romanian Retrospective Cohort
Objectives: This study aimed to evaluate the genetic and clinical characteristics of hereditary pancreatitis (HP) in a cohort of Romanian pediatric patients, with a focus on the correlation between specific gene mutations and disease severity, recurrence patterns, and associated complications. Methods: A retrospective analysis was conducted on pediatric patients diagnosed with HP. Genetic testing was performed to identify mutations in key genes. Clinical data were collected regarding age of onset, recurrence, severity, surgical interventions, and progression to chronic pancreatitis. Exploratory computational analyses were performed to illustrate potential patterns between genetic variants and clinical characteristics. Results: PRSS1 variants were associated with earlier onset and more severe disease. A substantial proportion of patients developed chronic pancreatitis during the study period. Surgical complications were observed in over half of the cohort. The findings are consistent with the role of genetic mutations in influencing the clinical trajectory of HP. Genotype–phenotype correlations may inform hypotheses regarding early risk stratification and tailored management strategies. Conclusions: Genetic testing is essential for the accurate diagnosis and personalized treatment of HP. Integrating genetic diagnostics into clinical practice may improve outcomes and guide early intervention in high-risk pediatric patients.
- Open Access
- 2 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6202
Neurodevelopmental Outcomes in Children Born to Mothers Infected with SARS-CoV-2 During Pregnancy: A Narrative Review
Background: The potential impact of maternal SARS-CoV-2 infection during pregnancy on the neurodevelopment of offspring has raised considerable concern. Emerging studies have evaluated various developmental domains in exposed infants, yet findings remain inconsistent. Objective: To synthesize current evidence regarding neurodevelopmental outcomes in infants born to mothers with confirmed SARS-CoV-2 infection during pregnancy. Methods: We conducted a narrative review following PRISMA guidelines. A literature search was performed in PubMed, Cochrane, and ScienceDirect using keywords including “COVID-19”, “pregnancy”, “neurodevelopment”, and “SARS-CoV-2”. Nineteen studies were included. Data were extracted regarding study design, sample size, timing of exposure, age at assessment, developmental tools used, and key findings. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Among 19 included studies, 12 reported at least some neurodevelopmental delays, particularly in motor and language domains. However, these delays were generally mild, domain-specific, and often not statistically significant. Seven studies, most of which were high-quality and low-risk, reported no significant differences between exposed and unexposed groups. Assessment tools and follow-up durations varied widely, limiting comparability. Conclusions: Current evidence does not support a consistent association between in utero SARS-CoV-2 exposure and an unfavorable neurodevelopmental outcome up to 24 months. However, heterogeneity in methods and short-term follow-up warrant further high-quality longitudinal research.
- 2 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6202
Open AccessNeurodevelopmental Outcomes in Children Born to Mothers Infected with SARS-CoV-2 During Pregnancy: A Narrative Review
Background: The potential impact of maternal SARS-CoV-2 infection during pregnancy on the neurodevelopment of offspring has raised considerable concern. Emerging studies have evaluated various developmental domains in exposed infants, yet findings remain inconsistent. Objective: To synthesize current evidence regarding neurodevelopmental outcomes in infants born to mothers with confirmed SARS-CoV-2 infection during pregnancy. Methods: We conducted a narrative review following PRISMA guidelines. A literature search was performed in PubMed, Cochrane, and ScienceDirect using keywords including “COVID-19”, “pregnancy”, “neurodevelopment”, and “SARS-CoV-2”. Nineteen studies were included. Data were extracted regarding study design, sample size, timing of exposure, age at assessment, developmental tools used, and key findings. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Among 19 included studies, 12 reported at least some neurodevelopmental delays, particularly in motor and language domains. However, these delays were generally mild, domain-specific, and often not statistically significant. Seven studies, most of which were high-quality and low-risk, reported no significant differences between exposed and unexposed groups. Assessment tools and follow-up durations varied widely, limiting comparability. Conclusions: Current evidence does not support a consistent association between in utero SARS-CoV-2 exposure and an unfavorable neurodevelopmental outcome up to 24 months. However, heterogeneity in methods and short-term follow-up warrant further high-quality longitudinal research.
- Open Access
- 24 August 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (9) , 855
Escherichia coli Urinary Tract Infections from a Romanian Pediatric Hospital: Antimicrobial Resistance Trends, ESBL Prevalence, and Empirical Treatment Implications
Background: Urinary tract infections (UTIs) are among the most common bacterial infections in children, with Escherichia coli as the leading pathogen. The rise in antimicrobial resistance, particularly extended-spectrum β-lactamase (ESBL) production, complicates empirical therapy, especially in countries with limited surveillance like Romania. Methods: We conducted a retrospective study on 248 pediatric patients aged 0–17 years diagnosed with E. coli UTI and admitted to a children hospital from Bucharest, Romania, between 2022 and 2024. Data collected included clinical presentation, laboratory values, and antimicrobial susceptibility testing. Patients were divided into ESBL and non-ESBL groups, and statistical comparisons were performed using SPSS v25. Results: Infants accounted for 68.1% of cases, with male sex predominating in this group (85.3%). ESBL-producing strains were identified in 19% of patients, more frequently in males (25% vs. 13.6%, p = 0.024). While inflammatory markers (CRP, leukocytes, neutrophils) were higher in complicated infections, they were paradoxically lower in ESBL cases. Non-ESBL isolates were highly susceptible to fosfomycin, third-generation cephalosporins, nitrofurantoin, and gentamicin. ESBL isolates showed resistance to most β-lactams but retained high susceptibility to fosfomycin (100%), carbapenems (>89%), cefoxitin (89.4%), and amikacin (85.1%). Conclusions: Our findings support the use of fosfomycin, nitrofurantoin, and selected aminoglycosides as viable empirical options in pediatric UTIs. Given the substantial ESBL prevalence and resistance to commonly used oral agents, local antibiogram data should guide empirical treatment strategies to preserve antibiotic efficacy and combat resistance.
- 24 August 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (9) , 855
Open AccessEscherichia coli Urinary Tract Infections from a Romanian Pediatric Hospital: Antimicrobial Resistance Trends, ESBL Prevalence, and Empirical Treatment Implications
Background: Urinary tract infections (UTIs) are among the most common bacterial infections in children, with Escherichia coli as the leading pathogen. The rise in antimicrobial resistance, particularly extended-spectrum β-lactamase (ESBL) production, complicates empirical therapy, especially in countries with limited surveillance like Romania. Methods: We conducted a retrospective study on 248 pediatric patients aged 0–17 years diagnosed with E. coli UTI and admitted to a children hospital from Bucharest, Romania, between 2022 and 2024. Data collected included clinical presentation, laboratory values, and antimicrobial susceptibility testing. Patients were divided into ESBL and non-ESBL groups, and statistical comparisons were performed using SPSS v25. Results: Infants accounted for 68.1% of cases, with male sex predominating in this group (85.3%). ESBL-producing strains were identified in 19% of patients, more frequently in males (25% vs. 13.6%, p = 0.024). While inflammatory markers (CRP, leukocytes, neutrophils) were higher in complicated infections, they were paradoxically lower in ESBL cases. Non-ESBL isolates were highly susceptible to fosfomycin, third-generation cephalosporins, nitrofurantoin, and gentamicin. ESBL isolates showed resistance to most β-lactams but retained high susceptibility to fosfomycin (100%), carbapenems (>89%), cefoxitin (89.4%), and amikacin (85.1%). Conclusions: Our findings support the use of fosfomycin, nitrofurantoin, and selected aminoglycosides as viable empirical options in pediatric UTIs. Given the substantial ESBL prevalence and resistance to commonly used oral agents, local antibiogram data should guide empirical treatment strategies to preserve antibiotic efficacy and combat resistance.
- Open Access
- 17 May 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 1152
The Clinical Profile of Pediatric M. pneumoniae Infections in the Context of a New Post-Pandemic Wave
Mycoplasma pneumoniae is an atypical bacterium with a tropism for the respiratory tract, but it can also cause numerous extrapulmonary involvements. The incidence of high rates varies in epidemiological waves, occurring at a frequency of 3–7 years. Since the end of 2023, an increase in the incidence of M. pneumoniae infection cases has been noted internationally. We conducted a retrospective study of children hospitalized and confirmed with M. pneumoniae infection in our clinic during the last two epidemiological peaks. We retrieved data from the hospital database and divided the patients into two groups, corresponding to the years 2018–2019 and 2023–2024, respectively. Fisher’s exact test was used to compare the proportions. In the years 2023–2024, we observed a higher incidence of patients with respiratory failure (p = 0.032), pleural reaction (p = 0.016), and pulmonary consolidation (p = 0.016) compared to the group in the years 2018–2019. Gastrointestinal involvement was more frequent in the years 2018–2019 (p = 0.004). The incidence of other extrapulmonary complications did not show significant differences. Infection with M. pneumoniae has varied clinical manifestations. In patients with community-acquired pneumonia, even in cases of consolidation, the possibility of infection with M. pneumoniae must also be considered.
- 17 May 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 1152
Open AccessThe Clinical Profile of Pediatric M. pneumoniae Infections in the Context of a New Post-Pandemic Wave
Mycoplasma pneumoniae is an atypical bacterium with a tropism for the respiratory tract, but it can also cause numerous extrapulmonary involvements. The incidence of high rates varies in epidemiological waves, occurring at a frequency of 3–7 years. Since the end of 2023, an increase in the incidence of M. pneumoniae infection cases has been noted internationally. We conducted a retrospective study of children hospitalized and confirmed with M. pneumoniae infection in our clinic during the last two epidemiological peaks. We retrieved data from the hospital database and divided the patients into two groups, corresponding to the years 2018–2019 and 2023–2024, respectively. Fisher’s exact test was used to compare the proportions. In the years 2023–2024, we observed a higher incidence of patients with respiratory failure (p = 0.032), pleural reaction (p = 0.016), and pulmonary consolidation (p = 0.016) compared to the group in the years 2018–2019. Gastrointestinal involvement was more frequent in the years 2018–2019 (p = 0.004). The incidence of other extrapulmonary complications did not show significant differences. Infection with M. pneumoniae has varied clinical manifestations. In patients with community-acquired pneumonia, even in cases of consolidation, the possibility of infection with M. pneumoniae must also be considered.
- Open Access
One Family with Cholestasis: The Twisted Road to the Diagnosis of Pfic 3—Three Case Reports
Background and Clinical Significance: Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal recessive disorders consisting of mutations of hepatocyte transporting-system genes involved in bile formation. The exact prevalence remains unknown but is estimated at 1 in 500.000 for PFIC 3, caused by mutations in the ABCB4 gene. We report three cases of PFIC 3 from the patient’s sister, brother, and cousin, diagnosed in our Pediatric Department in 2022–2023. Case Presentation: Case 1: A 10-year-old girl was admitted for jaundice and abdominal pain. She was diagnosed with severely advanced hepatic cirrhosis and massive cholestasis. Genetic testing showed ABCB4 homozygous mutation. She rapidly developed fulminant liver failure, and a living donor liver transplant was performed. Case 2: A 6-year-old brother was previously diagnosed with cholestatic hepatitis of unknown cause back in 2018 and presented with similar features (generalized jaundice, severe pruritus with generalized scratching lesions); symptoms had progressively developed from the first year of life. He also exhibited particular facial features (big forehead, twisted ear lobe, straight nose). He received cadaveric liver transplantation. Case 3: Nephew of first two children, a 3-year-5-month-old boy, was admitted for failure to thrive and a one-year history of jaundice, pruritus, and splenomegaly. He was tested positive for homozygous ABCB4 mutation. He is currently under medical treatment with stable liver function. Conclusions: The clinical significance of this particular homozygous variant identified in ABCB4 in our series of cases (c.2534G>T (p.Gly845Val)) was uncertain up to this case report. The present data provide convincing evidence as to the correlation between this mutation and the clinical phenotype of PFIC 3.
Open AccessOne Family with Cholestasis: The Twisted Road to the Diagnosis of Pfic 3—Three Case Reports
Background and Clinical Significance: Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal recessive disorders consisting of mutations of hepatocyte transporting-system genes involved in bile formation. The exact prevalence remains unknown but is estimated at 1 in 500.000 for PFIC 3, caused by mutations in the ABCB4 gene. We report three cases of PFIC 3 from the patient’s sister, brother, and cousin, diagnosed in our Pediatric Department in 2022–2023. Case Presentation: Case 1: A 10-year-old girl was admitted for jaundice and abdominal pain. She was diagnosed with severely advanced hepatic cirrhosis and massive cholestasis. Genetic testing showed ABCB4 homozygous mutation. She rapidly developed fulminant liver failure, and a living donor liver transplant was performed. Case 2: A 6-year-old brother was previously diagnosed with cholestatic hepatitis of unknown cause back in 2018 and presented with similar features (generalized jaundice, severe pruritus with generalized scratching lesions); symptoms had progressively developed from the first year of life. He also exhibited particular facial features (big forehead, twisted ear lobe, straight nose). He received cadaveric liver transplantation. Case 3: Nephew of first two children, a 3-year-5-month-old boy, was admitted for failure to thrive and a one-year history of jaundice, pruritus, and splenomegaly. He was tested positive for homozygous ABCB4 mutation. He is currently under medical treatment with stable liver function. Conclusions: The clinical significance of this particular homozygous variant identified in ABCB4 in our series of cases (c.2534G>T (p.Gly845Val)) was uncertain up to this case report. The present data provide convincing evidence as to the correlation between this mutation and the clinical phenotype of PFIC 3.
- Open Access
- 11 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1)
Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center
Background/Objectives: The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies. Methods: This retrospective, single-center study examined pediatric IBD patients receiving anti-TNF-α therapy at the “Grigore Alexandrescu” Emergency Hospital for Children in Bucharest, Romania, from January 2015 to October 2024. AEs were categorized into non-infectious complications (acute infusion reactions, anti-drug antibody formation), dermatological effects (erythema nodosum, vasculitis), neurological effects (Guillain–Barré syndrome), and infections. AEs were analyzed in relation to the specific anti-TNF-α agent administered and comprehensively characterized. Results: Of 40 patients enrolled, 22 (55%) had Crohn’s disease (CD). The median (IQR) age at diagnosis was 14.8 years [10.8–15.9]. IFX was used in 34 (85%) patients while 6 (15%) patients received either ADA or IFX/ADA sequential therapy. Twenty-seven AEs were documented in 19 (47.5%) patients, the most prevalent being antidrug antibody formation (44.4%), infections (22.2%), and acute infusion reactions (22.2%). All ADA-exposed patients experienced at least one AE, compared to 41.2% (n = 14) patients treated with IFX, p = 0.01. Conclusions: AEs were observed in approximately half of the study cohort, with anti-drug antibody formation emerging as the most frequent complication. ADA therapy was associated with a significantly higher rate of AEs compared to IFX. These findings underscore the critical importance of vigilant monitoring for patients undergoing anti-TNF-α therapy in pediatric IBD management.
- 11 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1)
Open AccessAnti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease—Reports from a Romanian Center
Background/Objectives: The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies. Methods: This retrospective, single-center study examined pediatric IBD patients receiving anti-TNF-α therapy at the “Grigore Alexandrescu” Emergency Hospital for Children in Bucharest, Romania, from January 2015 to October 2024. AEs were categorized into non-infectious complications (acute infusion reactions, anti-drug antibody formation), dermatological effects (erythema nodosum, vasculitis), neurological effects (Guillain–Barré syndrome), and infections. AEs were analyzed in relation to the specific anti-TNF-α agent administered and comprehensively characterized. Results: Of 40 patients enrolled, 22 (55%) had Crohn’s disease (CD). The median (IQR) age at diagnosis was 14.8 years [10.8–15.9]. IFX was used in 34 (85%) patients while 6 (15%) patients received either ADA or IFX/ADA sequential therapy. Twenty-seven AEs were documented in 19 (47.5%) patients, the most prevalent being antidrug antibody formation (44.4%), infections (22.2%), and acute infusion reactions (22.2%). All ADA-exposed patients experienced at least one AE, compared to 41.2% (n = 14) patients treated with IFX, p = 0.01. Conclusions: AEs were observed in approximately half of the study cohort, with anti-drug antibody formation emerging as the most frequent complication. ADA therapy was associated with a significantly higher rate of AEs compared to IFX. These findings underscore the critical importance of vigilant monitoring for patients undergoing anti-TNF-α therapy in pediatric IBD management.
- Open Access
- 30 December 2024
- Published by Instytut Badan Gospodarczych / Institute of Economic Research in Oeconomia Copernicana
- Vol. 15 (4) , 1349-1381
Generative artificial intelligence algorithms in Internet of Things blockchain-based fintech management
Research background: Big data-driven artificial Internet of Things (IoT) fintech algorithms can provide real-time personalized financial service access, strengthen risk management, and manage, monitor, and mitigate transaction operational risks by operational credit risk management, suspicious financial transaction abnormal pattern detection, and synthetic financial data-based fraud simulation. Blockchain technologies, automated financial planning and investment advice services, and risk scoring and fraud detection tools can be leveraged in financial trading forecasting and planning, cryptocurrency transactions, and financial workflow automation and fraud detection. Algorithmic trading and fraud detection tools, distributed ledger and cryptocurrency technologies, and ensemble learning and support vector machine algorithms are pivotal in predictive analytics-based risk mitigation, customer behavior and preference-based financial product and service personalization, and financial transaction and fraud detection automation. Credit scoring and risk management tools can offer financial personalized recommendations based on customer data, behavior, and preferences, in addition to transaction history, by generative adversarial and deep learning recurrent neural networks. Purpose of the article: We show that blockchain and edge computing technologies, generative artificial IoT-based fintech algorithms, and transaction monitoring and credit scoring tools can be harnessed in financial decision-making processes and loan default rate mitigation for transaction, payment, and credit process efficiency. Generative and predictive artificial intelligence (AI) algorithmic trading systems can drive coherent customer service operations, provide tailored financial and investment advice, and influence financial decision processing, while performing real-time risk assessment and financial and trading risk scenario simulation across fluctuating market conditions. Fraud and money laundering prevention tools, blockchain and financial transaction technologies, and federated and decentralized machine learning algorithms can articulate algorithmic profiling-based transaction data patterns and structures, credit assessment, loan repaying likelihood prediction, and interest rate and credit lending risk management by real-time financial pattern and economic forecast-based credit analysis across investment payment and transaction record infrastructures. Methods: Research published between 2023 and 2024 was identified and analyzed across ProQuest, Scopus, and the Web of Science databases by use of screening and quality assessment software systems such as Abstrackr, AMSTAR, AXIS, CADIMA, CASP, Catchii, DistillerSR, Eppi-Reviewer, MMAT, Nested Knowledge, PICO Portal, Rayyan, ROBIS, and SRDR+. Findings & value added: The main value added derived from the systematic literature review is that generative AI-based operational risk management, fraud detection, and transaction monitoring tools can provide personalized financial support and services and clarify financial and credit decisions and operations by financial decision-making process automation in dynamic business environments based on fraud detection capabilities and transaction data analysis and assessment. The benefits for theory and current state of the art are that credit risk and financial forecasting tools, artificial IoT-based fintech and generative AI algorithms, and algorithmic trading and distributed ledger technologies can be deployed in financial decision-making and customer behavior pattern optimization, credit score assessment, and money laundering and fraudulent payment detection. Policy implications reveal that investment management and algorithmic credit scoring tools can streamline financial activity operational efficiency, design financial planning analysis and forecasting, and carry out financial service and transaction data analysis for informed transaction decision-making and fraudulent behavior pattern and incident detection, taking into account credit history and risk evaluation and improving personalized experiences.
- 30 December 2024
- Published by Instytut Badan Gospodarczych / Institute of Economic Research in Oeconomia Copernicana
- Vol. 15 (4) , 1349-1381
Open AccessGenerative artificial intelligence algorithms in Internet of Things blockchain-based fintech management
Research background: Big data-driven artificial Internet of Things (IoT) fintech algorithms can provide real-time personalized financial service access, strengthen risk management, and manage, monitor, and mitigate transaction operational risks by operational credit risk management, suspicious financial transaction abnormal pattern detection, and synthetic financial data-based fraud simulation. Blockchain technologies, automated financial planning and investment advice services, and risk scoring and fraud detection tools can be leveraged in financial trading forecasting and planning, cryptocurrency transactions, and financial workflow automation and fraud detection. Algorithmic trading and fraud detection tools, distributed ledger and cryptocurrency technologies, and ensemble learning and support vector machine algorithms are pivotal in predictive analytics-based risk mitigation, customer behavior and preference-based financial product and service personalization, and financial transaction and fraud detection automation. Credit scoring and risk management tools can offer financial personalized recommendations based on customer data, behavior, and preferences, in addition to transaction history, by generative adversarial and deep learning recurrent neural networks. Purpose of the article: We show that blockchain and edge computing technologies, generative artificial IoT-based fintech algorithms, and transaction monitoring and credit scoring tools can be harnessed in financial decision-making processes and loan default rate mitigation for transaction, payment, and credit process efficiency. Generative and predictive artificial intelligence (AI) algorithmic trading systems can drive coherent customer service operations, provide tailored financial and investment advice, and influence financial decision processing, while performing real-time risk assessment and financial and trading risk scenario simulation across fluctuating market conditions. Fraud and money laundering prevention tools, blockchain and financial transaction technologies, and federated and decentralized machine learning algorithms can articulate algorithmic profiling-based transaction data patterns and structures, credit assessment, loan repaying likelihood prediction, and interest rate and credit lending risk management by real-time financial pattern and economic forecast-based credit analysis across investment payment and transaction record infrastructures. Methods: Research published between 2023 and 2024 was identified and analyzed across ProQuest, Scopus, and the Web of Science databases by use of screening and quality assessment software systems such as Abstrackr, AMSTAR, AXIS, CADIMA, CASP, Catchii, DistillerSR, Eppi-Reviewer, MMAT, Nested Knowledge, PICO Portal, Rayyan, ROBIS, and SRDR+. Findings & value added: The main value added derived from the systematic literature review is that generative AI-based operational risk management, fraud detection, and transaction monitoring tools can provide personalized financial support and services and clarify financial and credit decisions and operations by financial decision-making process automation in dynamic business environments based on fraud detection capabilities and transaction data analysis and assessment. The benefits for theory and current state of the art are that credit risk and financial forecasting tools, artificial IoT-based fintech and generative AI algorithms, and algorithmic trading and distributed ledger technologies can be deployed in financial decision-making and customer behavior pattern optimization, credit score assessment, and money laundering and fraudulent payment detection. Policy implications reveal that investment management and algorithmic credit scoring tools can streamline financial activity operational efficiency, design financial planning analysis and forecasting, and carry out financial service and transaction data analysis for informed transaction decision-making and fraudulent behavior pattern and incident detection, taking into account credit history and risk evaluation and improving personalized experiences.